anti-ERb3 human mAb (Recalcine/University of Chile)

N/A

Report date: 2025/03/14 16:41:26

Base Information

Drug Nameanti-ERb3 human mAb (Recalcine/University of Chile)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists

TargetsReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryChile

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRecalcine Pharmaceutical Corp

China Registration ClassN/A

Develop Information

Active CompaniesRecalcine Pharmaceutical Corp University Of Chile

Inactive CompaniesN/A

Active IndicationsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A